Prudential Financial Inc Kezar Life Sciences, Inc. Transaction History

Prudential Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.72 - $1.15 $12,636 - $20,182	-17,550 Reduced 48.04%	18,980 $18,000
Q3 2023 Nov 13, 2023	BUY	$1.08 - $2.54 $7,236 - $17,018	6,700 Added 22.46%	36,530 $43,000
Q2 2023 Aug 11, 2023	SELL	$2.31 - $3.06 $116,655 - $154,530	-50,500 Reduced 62.87%	29,830 $73,000
Q1 2023 May 12, 2023	BUY	$3.13 - $7.31 $251,432 - $587,212	80,330 New	80,330 $251,000
Q4 2021 Feb 14, 2022	SELL	$7.44 - $16.72 $93,491 - $210,103	-12,566 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.85 - $9.73 $5,810 - $11,656	1,198 Added 10.54%	12,566 $109,000
Q2 2021 Aug 16, 2021	SELL	$4.93 - $6.46 $102,987 - $134,949	-20,890 Reduced 64.76%	11,368 $61,000
Q1 2021 May 12, 2021	SELL	$5.24 - $6.99 $32,377 - $43,191	-6,179 Reduced 16.08%	32,258 $192,000
Q4 2020 Feb 16, 2021	SELL	$4.77 - $6.58 $50,228 - $69,287	-10,530 Reduced 21.5%	38,437 $201,000
Q3 2020 Nov 16, 2020	BUY	$4.36 - $5.5 $2,485 - $3,135	570 Added 1.18%	48,967 $237,000
Q2 2020 Aug 12, 2020	BUY	$3.6 - $7.75 $174,229 - $375,076	48,397 New	48,397 $250,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $449M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.